Jeffrey Becker

Co-founder & CSO

Bexson Biomedical

Jeffrey is the Co-Founder and CSO of Noetic’säportfolio company, Bexson Biomedical. Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He was one of the first MDs in the U.S. administering and documenting ketamine for depression in the clinic, and is a world recognized speaker and expert in the clinical use of ketamine. His expertise led to the development of an effective nutraceutical product addressing NMDA-receptor abnormalities. He maintains a clinical practice focused in Functional Psychiatry and novel treatment approaches to mental health challenges.

Prior to starting Bexson Biomedical, Dr. Becker held a private practice for 17 years surrounding discovery and treatment of root-cause metabolic, nutrient-based and genetic mechanisms in syndromic illness and complex mental health conditions such as schizophrenia, treatment resistant depression, traumatic brain injury, polycystic ovarian syndrome, narcolepsy & idiopathic hypersomnia, peripheral neuropathy, functional B12 deficiency, dementia & cognitive dysfunction, and traumatic brain injury. 

Dr. Becker received his B.S. from UC Berkeley in Biology, Entomology & Religious Mysticism and M.D from UCLA, where he also completed his psychiatry residency.